Eli Lilly recently announced that it has requested that the European Medicines Agency (EMA) reexamine Keysunra, its Alzheimer’s medication.
Keytruda’s approval was denied by the European regulator last month due to the possibility of severe brain swelling.
The European regulator intends to grant Eli Lilly’s request for a reexamination and provide a final Keytruda recommendation.
Meanwhile, Keytruda has already received approval from the U.S. Food and Drug Administration (FDA) and is currently available in the United States.
